Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Taiwanese (TAIEX) Pharma Industry Analysis

UpdatedOct 03, 2025
DataAggregated Company Financials
Companies56
  • 7D1.8%
  • 3M23.4%
  • 1Y20.2%
  • YTD33.7%

In the last week, the Pharma industry is up 1.4%, with Lotus Pharmaceutical up 14%. In the last 12 months, the industry was up 21%. As for the next few years, earnings are expected to grow by 134% per annum.

Industry Valuation and Performance

Has the Taiwanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Oct 2025NT$835.8bNT$118.3bNT$9.6b16.5x86.9x7.1x
Sun, 31 Aug 2025NT$814.3bNT$118.3bNT$10.3b16.3x79.1x6.9x
Tue, 29 Jul 2025NT$685.7bNT$116.0bNT$14.3b18.4x48x5.9x
Thu, 26 Jun 2025NT$662.6bNT$115.9bNT$14.3b18.5x46.5x5.7x
Sat, 24 May 2025NT$606.4bNT$115.9bNT$14.3b19.4x42.5x5.2x
Mon, 21 Apr 2025NT$536.1bNT$112.8bNT$10.8b18x49.6x4.8x
Wed, 19 Mar 2025NT$654.6bNT$113.3bNT$12.2b20.3x53.5x5.8x
Fri, 14 Feb 2025NT$671.4bNT$109.3bNT$11.4b22.8x58.7x6.1x
Sun, 12 Jan 2025NT$611.6bNT$109.3bNT$11.4b21.4x53.5x5.6x
Tue, 10 Dec 2024NT$594.8bNT$109.3bNT$11.4b22x52x5.4x
Thu, 07 Nov 2024NT$624.7bNT$104.7bNT$8.9b26.1x69.9x6x
Sat, 05 Oct 2024NT$631.9bNT$104.7bNT$8.9b26x70.7x6x
Mon, 02 Sep 2024NT$664.6bNT$104.7bNT$8.9b26.6x74.3x6.3x
Wed, 31 Jul 2024NT$661.8bNT$100.5bNT$6.8b30.8x96.9x6.6x
Fri, 28 Jun 2024NT$677.8bNT$100.4bNT$7.2b32.1x94.7x6.8x
Sun, 26 May 2024NT$622.7bNT$100.4bNT$7.1b32.4x87.1x6.2x
Tue, 23 Apr 2024NT$605.4bNT$101.8bNT$9.4b24.6x64.7x5.9x
Thu, 21 Mar 2024NT$624.1bNT$100.9bNT$9.4b25.4x66.2x6.2x
Sat, 17 Feb 2024NT$609.4bNT$101.6bNT$8.2b24x74.7x6x
Mon, 15 Jan 2024NT$575.6bNT$101.9bNT$7.8b24.2x73.9x5.7x
Wed, 13 Dec 2023NT$576.3bNT$101.6bNT$7.6b24x75.6x5.7x
Fri, 10 Nov 2023NT$569.7bNT$101.8bNT$9.6b22.2x59.1x5.6x
Sun, 08 Oct 2023NT$548.3bNT$101.7bNT$9.6b21.6x57x5.4x
Tue, 05 Sep 2023NT$561.1bNT$101.7bNT$9.6b22.7x58.3x5.5x
Thu, 03 Aug 2023NT$571.8bNT$98.7bNT$10.1b16.8x56.8x5.8x
Sat, 01 Jul 2023NT$609.6bNT$98.7bNT$10.1b17.4x60.6x6.2x
Mon, 29 May 2023NT$575.1bNT$97.9bNT$11.0b18.3x52.3x5.9x
Wed, 26 Apr 2023NT$556.9bNT$92.1bNT$8.6b22.1x64.4x6x
Fri, 24 Mar 2023NT$546.2bNT$90.2bNT$7.8b19.8x69.9x6.1x
Sun, 19 Feb 2023NT$554.2bNT$84.6bNT$7.9b24.7x70.3x6.5x
Tue, 17 Jan 2023NT$482.8bNT$84.6bNT$7.9b20.6x61.2x5.7x
Thu, 15 Dec 2022NT$501.4bNT$84.6bNT$7.9b21.5x63.6x5.9x
Sat, 12 Nov 2022NT$427.6bNT$80.0bNT$4.7b16.9x91.3x5.3x
Mon, 10 Oct 2022NT$439.6bNT$78.9bNT$4.3b17.4x101.6x5.6x
Price to Earnings Ratio

101.6x


Total Market Cap: NT$439.6bTotal Earnings: NT$4.3bTotal Revenue: NT$78.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Pharma Industry Price to Earnings3Y Average 66.4x202320242025
Current Industry PE
  • Investors are optimistic on the Taiwanese Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 87.5x which is higher than its 3-year average PE of 66.5x.
  • The 3-year average PS ratio of 5.9x is lower than the industry's current PS ratio of 7.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 30% per year over the last three years.
  • Revenues for these companies have grown 14% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare industry?

TW Market1.23%
Healthcare1.00%
Pharma1.82%
Pharma1.82%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6785 Alar PharmaceuticalsNT$282.0032.1%
+NT$4.6b		58.0%PS2664.4x
6620 Handa PharmaceuticalsNT$144.5022.5%
+NT$4.2b		104.1%PE36.5x
1795 Lotus PharmaceuticalNT$266.004.3%
+NT$2.9b		3.1%PE14.4x
6535 Lumosa TherapeuticsNT$294.002.8%
+NT$1.3b		-5.6%PS1329.6x
6472 Bora PharmaceuticalsNT$688.001.2%
+NT$993.0m		12.3%PE16.7x

Latest News

6620
NT$144.50
Handa Pharmaceuticals
7D
22.5%
1Y
104.1%
6472
NT$688.00
Bora Pharmaceuticals
7D
1.2%
1Y
12.3%

US CDMO Expansion And Specialty Focus Will Strengthen Position

The consensus analyst price target for Bora Pharmaceuticals has been revised upward, primarily driven by a significant increase in the company's expected future P/E multiple, with the fair value rising from NT$847.46 to NT$872.67. What's in the News Bora Pharmaceuticals is making significant investments to expand manufacturing and packaging capabilities at its Maple Grove, Minnesota facility, acquired via the $210 million Upsher-Smith Laboratories deal in 2024.
4123
NT$35.70
Center Laboratories
7D
-3.4%
1Y
-20.7%
6535
NT$294.00
Lumosa Therapeutics
7D
2.8%
1Y
-5.6%
1795
NT$266.00
Lotus Pharmaceutical
7D
4.3%
1Y
3.1%

Alpha Choay Acquisition And New R&D Center Will Strengthen Southeast Asia Presence

The upward revision in Lotus Pharmaceutical's consensus price target reflects sharply improved revenue growth forecasts and a substantially lower future P/E, raising the fair value estimate from NT$322.40 to NT$346.00. Valuation Changes Summary of Valuation Changes for Lotus Pharmaceutical The Consensus Analyst Price Target has risen from NT$322.40 to NT$346.00.
1271
NT$71.10
SunWay Biotech
7D
-4.6%
1Y
-16.2%
4743
NT$65.20
Oneness Biotech
7D
-3.0%
1Y
-54.1%
6919
NT$178.50
Caliway Biopharmaceuticals
7D
-3.3%
1Y
244.6%
7829
NT$62.70
Yoda Pharmaceuticals
7D
17.0%
1Y
n/a
1789
NT$20.15
ScinoPharm Taiwan
7D
6.6%
1Y
-19.6%
1799
NT$51.40
Easywell Biomedicals
7D
11.3%
1Y
-51.7%
4119
NT$58.90
SCI Pharmtech
7D
-2.2%
1Y
-35.8%
1720
NT$55.60
Standard Chemical & Pharmaceutical
7D
-1.2%
1Y
-12.6%
6785
NT$282.00
Alar Pharmaceuticals
7D
32.1%
1Y
58.0%
6935
NT$31.95
Prince Pharmaceutical
7D
-9.0%
1Y
43.0%
6467
NT$168.50
Taho Pharmaceuticals
7D
-9.7%
1Y
n/a